相关实验视频

Updated: Feb 22, 2026

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells

Published on: November 18, 2022

欧巴利诺利德B通过PI3K/Akt/GSK3β(Ser9) 信号通路预防大脑缺血-再输血损伤

Man Li¹, Yuxin Jiang¹, Yongkang Xue¹

¹Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University College of Pharmacy, Yanji 133002, PR China.

Bioorganic chemistry

|February 20, 2026

概括

欧巴利诺化B (EB) 通过保护大脑细胞,在治疗缺血性中风方面表现有前途. 这项研究表明,EB激活PI3K/Akt/GSK3β信号通路,减少神经元损伤并改善中风模型的结果.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

缺血性中风 (IS) 是全球死亡和残疾的主要原因,特别是在中国.
来自Eupatorium lindleyanum的Eupalinolide B (EB) 已知具有神经保护性,但其针对脑缺血-再输伤害 (CIRI) 的机制需要进一步澄清.

研究的目的:

研究Eupalinolide B (EB) 的治疗点和分子机制,用于治疗脑缺血再输液损伤 (CIRI).
评估EB在缺血性中风的体外和体内模型中的疗效.

主要方法:

网络药理学分析以确定EB的治疗点.
在PC12细胞中的体外氧-葡萄糖剥夺/重氧化 (OGD/R),以评估细胞活力,活性氧物种 (ROS) 和线粒体潜力.
在小鼠体内中脑动脉封闭/再输 (MCAO/R) 模型中,评估神经学缺陷,心脏病发作大小和神经元病理.

主要成果:

EB调节了54个核心治疗点,包括细胞亡调节剂和PI3K/Akt路径组件.
在体外,EB增强了PC12细胞活力,减少了ROS,并在OGD/R后恢复了线粒体膜潜力.
在体内,EB给药激活了PI3K/Akt/GSK3β(Ser9) 途径,降低了MCAO/R小鼠的神经缺陷,心脏病发作区域和神经元损伤.

结论:

欧巴利诺化B (EB) 抑制神经元亡,并对脑缺血-再输液损伤 (CIRI) 有预防作用.
神经保护机制涉及PI3K/Akt/GSK3β(Ser9) 信号通路的激活.
埃博基因表现出作为缺血性中风的新型治疗剂的潜力.

关键词:

细胞亡是细胞的亡.大脑缺血-再输血损伤欧巴利诺化物B B 在PI3K/Akt/GSK3β(Ser9) 信号通路中.

更多相关视频

Author Spotlight: Enhancing Cerebral Ischemia Research with a Simplified Rat Model

Author Spotlight: Enhancing Cerebral Ischemia Research with a Simplified Rat Model

Published on: July 5, 2024

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

相关概念视频

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

IP3/DAG Signaling Pathway

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...